Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Regeneron and Bayer begin phase III study of VEGF Trap-Eye for wet AMD

Aug. 8, 2007

Orphan drug designation of LX-211 recommended by EMEA committee

Aug. 7, 2007

TargeGen begins phase II trial of TG-100801 eye drops for AMD

Aug. 6, 2007

Alcon's Travatanz approved in Japan for glaucoma and ocular hypertension

Aug. 2, 2007

OSI transfers all rights to E-10030 and PDGF program to Ophthotech

July 31, 2007

Bausch & Lomb Ireland withdraws Retisert marketing authorization application

July 27, 2007

Preclinical antiglaucomal efficacy of the novel prostanoid FP receptor agonist tafluprost presented

July 24, 2007

Acadia receives milestone payment for drug candidate for glaucoma

July 20, 2007

Opko Health initiates phase III trial of bevasiranib in wet AMD

July 18, 2007

Jerini Ophthalmic's IND for JSM-6427 for AMD accepted by FDA

July 17, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...